Protagonist Therapeutics, Inc (PTGX) Return on equity 2017–2025
Protagonist Therapeutics, Inc (PTGX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-21.2%FY2025 · since FY2017: -30.6% → -21.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -21.2% | -61.9 pp |
| FY2024 | 40.8% | +64.2 pp |
| FY2023 | -23.5% | +35.6 pp |
| FY2022 | -59.1% | -17.2 pp |
| FY2021 | -41.8% | -18.2 pp |
| FY2020 | -23.7% | +72.9 pp |
| FY2019 | -96.5% | -61.9 pp |
| FY2018 | -34.6% | -4.0 pp |
| FY2017 | -30.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More PTGX financial trends
PTGX RevenuePTGX Net incomePTGX Net marginPTGX Gross profitPTGX Gross marginPTGX Operating incomePTGX Operating marginPTGX Operating cash flowPTGX Free cash flowPTGX Capital expendituresPTGX Stock buybacksPTGX Dividends paidPTGX Total assetsPTGX Total liabilitiesPTGX Shareholders’ equityPTGX overview →